| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
|
Pain
|
2004
|
2.30
|
|
2
|
Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
|
J Clin Oncol
|
2012
|
2.27
|
|
3
|
Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae.
|
Ann Surg
|
2009
|
1.47
|
|
4
|
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
|
BMC Cancer
|
2013
|
1.09
|
|
5
|
Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
|
J Clin Endocrinol Metab
|
2013
|
1.06
|
|
6
|
The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey.
|
Int J Rehabil Res
|
2010
|
1.05
|
|
7
|
Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice.
|
BMJ Open
|
2013
|
0.94
|
|
8
|
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
|
Clin Endocrinol (Oxf)
|
2008
|
0.92
|
|
9
|
Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial.
|
Neurorehabil Neural Repair
|
2012
|
0.91
|
|
10
|
Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
|
BJU Int
|
2014
|
0.86
|
|
11
|
Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study.
|
BMJ Open
|
2012
|
0.84
|
|
12
|
Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.
|
Funct Neurol
|
2013
|
0.80
|
|
13
|
Characterizing short stature by insulin-like growth factor axis status and genetic associations: results from the prospective, cross-sectional, epidemiogenetic EPIGROW study.
|
J Clin Endocrinol Metab
|
2013
|
0.77
|
|
14
|
Inappropriate conclusions from the use of botulinum toxin for the treatment of spasticity.
|
Clin Neuropharmacol
|
2009
|
0.75
|
|
15
|
Inappropriate citations used to describe the pharmacology of botulinum toxin type A preparations in clinical use.
|
J Rehabil Med
|
2009
|
0.75
|
|
16
|
Poster 313 Relationship Between AbobotulinumtoxinA Injections into Shoulder Muscles and Patient Centred Primary Goal Selection and Achievement: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study.
|
PM R
|
2016
|
0.75
|
|
17
|
Poster 373-C Integrated Upper Limb Spasticity Management Including Botulinum Toxin A (BoNT-A) on Patient-Centered Goal Attainment: Methodology for ULIS-III and Initial Goal-Setting Data.
|
PM R
|
2016
|
0.75
|
|
18
|
Poster 498 Geographic Differences in the Characteristics of Cervical Dystonia Patients.
|
PM R
|
2016
|
0.75
|
|
19
|
Poster 182 Baseline Characteristics of Cervical Dystonia Subjects in Observational Routine-Practice Studies are Different to Those from Randomized Controlled Trials.
|
PM R
|
2016
|
0.75
|
|
20
|
Poster 187 Is There a Correlation Between Tremor and Other Symptoms of Cervical Dystonia? An Analysis of Data from the Ongoing INTEREST IN CD2 Study.
|
PM R
|
2016
|
0.75
|